FDA Approves Regeneron and Sanofi's Dupixent (dupilumab) For Eosinophilic Esophagitis (EoE) Ahead of Schedule
The U.S. Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals, Inc.
Benzinga ·
Get all your news in one place.
100's of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100's of premium titles. One news app.
The Latest Breaking News from Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Earnings Perspective: Return On Capital Employed
Pulled from Benzinga Pro data, Regeneron Pharmaceuticals (NASDAQ:REGN) posted Q1 earnings of $973.50 million, an increase from Q4 of 56.33%. Sales dropped to $2.96 billion, a 40.13% decrease between quarters.
Benzinga ·
$1000 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth This Much
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 12.55% on an annualized basis producing an average annual return of 19.7%. Currently, Regeneron Pharmaceuticals has a market capitalization of $72.59 billion.
Benzinga ·
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Read news from The Economist, FT, and more,
with one subscription
with one subscription
If You Invested $100 In Regeneron Pharmaceuticals 10 Years Ago, Here's How Much You Would Have Today
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 10 years by 6.58% on an annualized basis producing an average annual return of 18.92%. Currently, Regeneron Pharmaceuticals has a market capitalization of $78.02 billion.
Benzinga ·
Analyst Ratings for Regeneron Pharmaceuticals
Regeneron Pharmaceuticals (NASDAQ:REGN) has observed the following analyst ratings within the last quarter:
Benzinga ·
This Is What Whales Are Betting On Regeneron Pharmaceuticals
A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals.
Looking at options history for Regeneron Pharmaceuticals (NASDAQ:REGN) we detected 11 strange trades.
Benzinga ·
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 11.29% on an annualized basis producing an average annual return of 18.54%. Currently, Regeneron Pharmaceuticals has a market capitalization of $77.02 billion.
Benzinga ·
Executives Sell More Than $262M Of 5 Stocks
Although gold futures traded higher on Monday, there were a few notable insider trades.
Benzinga ·
Overview Of Value Stocks In The Healthcare Sector
What are Value Stocks?
Benzinga ·
Recap: Regeneron Pharmaceuticals Q4 Earnings
Regeneron Pharmaceuticals (NASDAQ:REGN) reported its Q4 earnings results on Friday, February 4, 2022 at 06:30 AM.
Here's what investors need to know about the announcement.
Benzinga ·
Get all your
news in one place.
news in one place.
100's of premium titles.
One news app.
One news app.
Coverage From
Benzinga
Barchart
StockNews.com
Top News
Kiplinger
MarketBeat
The Guardian - US
The Independent UK
Organisations
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Topics
Read news from The Economist, FT, and more,
with one subscription
with one subscription
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.
100+ trusted global sources.
